OPRX earnings analysis
What we found in OPRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
OptimizeRx reported Q2 revenue of $20.504 million and non-GAAP diluted EPS of $0.16, exceeding consensus estimates, but GAAP diluted EPS was $(0.04). The 10-Q highlights continued remediation of a material weakness, with 3 of 4 third-party service organizations remediated and 1 remaining. No material risk-factor changes were disclosed versus the 2025 10-K, but ineffective disclosure controls and the remaining third-party data weakness are material concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Estimates
- Q2 revenue was $20.504 million, modestly above the $20.2592 million consensus estimate by approximately 1.2%.
- Adjusted EPS Beat, GAAP Loss
- Non-GAAP diluted EPS was $0.16 versus the $0.09 estimate, a $0.07 beat; however, GAAP diluted EPS was $(0.04).
- Control Remediation Progress
- Management stated that it remediated the material weakness for 3 of 4 third-party service organizations during 2025, leaving 1 organization in the process of full remediation.
- No Material Legal Proceedings
- The company reported no material legal or administrative proceedings and no pending or threatened material proceedings.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Weakness Remains
- Disclosure controls and procedures were not effective as of June 30, 2026 because of a material weakness involving controls over the completeness and accuracy of data received from 1 remaining third-party service organization.
- Third-Party Data Control Risk
- The company relies on SOC-1 Type 2 reports from each third-party service organization; if such a report or substantive testing is unavailable, it may need to modify contracts, limit activity, or add operational controls.
- GAAP Profitability Gap
- GAAP diluted EPS was $(0.04), despite non-GAAP diluted EPS of $0.16, indicating a $0.20 difference between GAAP and adjusted earnings measures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
What they said about what is next.
The 10-Q does not provide explicit quantitative guidance. Fiscal 2026 revenue guidance of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million were reaffirmed in the August 12, 2026 earnings release, not in the extracted 10-Q text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- OptimizeRx reported a Q1 2026 revenue of $19.8 million, showing a 10% decline year-over-year but exceeding consensus estimates. The company achieved an EPS of $0.14, significantly ahead of the expected loss of $0.02,…
- 10-K · March 12, 2026
- OptimizeRx’s 2025 10‑K describes a strategic shift toward subscriptionable, AI-enabled DAAP and MNT offerings and an explicit goal to be a “Rule of 40” company within the next several years. Financially, the company…
- 10-Q · November 7, 2025
- OptimizeRx reported a strong quarter: net revenue rose 22% year-over-year to $26,067 for Q3 2025, gross margin expanded to 67.2% and the company returned to profitability with net income of $779 (three months ended…
- 10-Q · August 8, 2025
- OptimizeRx reported a strong quarter ended June 30, 2025 with net revenue up 55% year-over-year to $29,195,000 and a return to profitability with net income of $1,532,000 for the quarter. Gross margin expanded to 63.8%…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OPRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever